Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient
Ji Hoon Baang, Christopher Smith, Carmen Mirabelli, Andrew L Valesano, David M Manthei, Michael A Bachman, Christiane E Wobus, Michael Adams, Laraine Washer, Emily T Martin, Adam S Lauring, Ji Hoon Baang, Christopher Smith, Carmen Mirabelli, Andrew L Valesano, David M Manthei, Michael A Bachman, Christiane E Wobus, Michael Adams, Laraine Washer, Emily T Martin, Adam S Lauring
Abstract
We describe a case of chronic coronavirus disease 2019 (COVID-19) in a patient with lymphoma and associated B-cell immunodeficiency. Viral cultures and sequence analysis demonstrate ongoing replication of infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for at least 119 days. The patient had 3 admissions related to COVID-19 over a 4-month period and was treated twice with remdesivir and convalescent plasma with resolution of symptoms. The patient's lack of seroconversion and prolonged course illustrate the importance of humoral immunity in resolving SARS-CoV-2 infection. This case highlights challenges in managing immunocompromised hosts, who may act as persistent shedders and sources of transmission.
Keywords: COVID-19; SARS-CoV-2; antibody; evolution; immunocompromise.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Figures
References
- Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324:782–93.
- Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients [manuscript published online ahead of print 19 August 2020]. Clin Infect Dis 2020. doi:10.1093/cid/ ciaa460.
- Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples [manuscript published online ahead of print 22 May 2020]. Clin Infect Dis 2020. doi:10.1093/cid/ ciaa638.
- Rhee C, Kanjilal S, Baker M, Klompas M. Duration of SARS-CoV-2 infectivity: when is it safe to discontinue isolation? [manuscript published online ahead of print August 25 2020]. Clin Infect Dis 2020. doi:10.1093/cid/ ciaa1249.
- Randall RE, Griffin DE. Within host RNA virus persistence: mechanisms and consequences. Curr Opin Virol 2017; 23:35–42.
- Deen GF, Broutet N, Xu W, et al. Ebola RNA persistence in semen of Ebola virus disease survivors—final report. N Engl J Med 2017; 377:1428–37.
- Jacobs M, Rodger A, Bell DJ, et al. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 2016; 388:498–503.
- Bok K, Prevots DR, Binder AM, et al. Epidemiology of norovirus infection among immunocompromised patients at a tertiary care research hospital, 2010–2013. Open Forum Infect Dis 2016; 3:ofw169.
- Lumby CK, Zhao L, Oporto M, et al. Favipiravir and zanamivir cleared infection with influenza B in a severely immunocompromised child [manuscript published online ahead of print 3 March 2020]. Clin Infect Dis 2020. doi:10.1093/cid/ciaa023.
- Dunn G, Klapsa D, Wilton T, Stone L, Minor PD, Martin J. Twenty-eight years of poliovirus replication in an immunodeficient individual: impact on the Global Polio Eradication Initiative. PLoS Pathog 2015; 11:e1005114.
- DeVries AS, Harper J, Murray A, et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med 2011; 364:2316–23.
- Debbink K, Lindesmith LC, Ferris MT, et al. Within-host evolution results in antigenically distinct GII.4 noroviruses. J Virol 2014; 88:7244–55.
- Xue KS, Stevens-Ayers T, Campbell AP, et al. Parallel evolution of influenza across multiple spatiotemporal scales. eLife 2017; 6:e26875.
- van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et al. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. medRxiv [Preprint]. Posted online 9 June 2020. . Accessed 9 July 2020.
Source: PubMed